Skip to main content
. 2022 Sep 21;315(3):521–530. doi: 10.1007/s00403-022-02398-0

Fig. 2.

Fig. 2

Biweekly follow-up for percent reduction in the hypopigmented lesions and the rash as a whole in azithromycin and NB-UVB groups